Results 141 to 150 of about 3,496 (176)

The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations

Journal of Applied Genetics, 2014
The vitamin K epoxide reductase (VKORC1) is a key enzyme in the vitamin K cycle impacting various biological processes. VKORC1 genetic variability has been extensively studied in the context of warfarin pharmacogenetics revealing different distributions of VKORC1 haplotypes in various populations.
Sophia, Sominsky, Michael, Korostishevsky, Daniel, Kurnik, Eleni, Aklillu, Yoram, Cohen, Gie, Ken-Dror, Ronen, Loebstein, Hillel, Halkin, Eva, Gak   +8 more
openaire   +2 more sources

VKORC1 and the Vitamin K Cycle

2008
Vitamin K epoxide, a product of gamma-carboxylation, must be rapidly recycled to its reduced form before it can be reused. The set of sequential reactions that guarantees vitamin K recycling is known as the vitamin K cycle. This review is focused on biochemical and genetic aspects of a recently characterized key enzyme of the cycle named vitamin K ...
Andrea A, Garcia, Pieter H, Reitsma
openaire   +2 more sources

VKORC1 Polymorphisms in Amerindian Populations of Brazil

Pharmacogenomics, 2008
Noncoding polymorphisms in the VKORC1 gene associate with variation of interindividual dosing requirements of warfarin and other coumarin anticoagulants. The frequency of VKORC1 polymorphisms displays distinct interpopulation differences. Here, we report the distribution of the VKORC1 3673G>A, 5808T>G, 6853G>C and 9041G>A SNPs in three endogamous ...
Jamila A, Perini, Maria Luiza, Petzl-Erler, Luiza Tamie, Tsuneto, Guilherme, Suarez-Kurtz   +3 more
openaire   +2 more sources

Identification of VKORC1 genotype leading to resistance to tecarfarin

The Journal of Clinical Pharmacology, 2014
The VKORC1 gene codes for the VKORC1 enzyme that is responsible for the reduction of vitamin K epoxide into vitamin K. VKORC1 enzyme is the target of vitamin K antagonists (VKA). The use of VKA in human medicine is difficult because of inter-individual variability in VKA requirements. This variability is partly due to basic physiological parameters but
Matagrin, Benjamin, Montagut-Romans, Adrien, Damin, Marlene, Lemaire, Marc, Popowycz, Florence, Benoit, Etienne, Lattard, Virginie   +6 more
openaire   +3 more sources

VKORC1: the little big protein

Blood, 2005
Comment on Sun et al, page [3811][1] VKORC1, the recently identified protein of the vitamin K cycle, catalyzes vitamin K epoxide to vitamin K and further to vitamin K hydroquinone, thus representing the rate-limiting enzyme for the carboxylation of vitamin K–dependent proteins.
openaire   +1 more source

Speculations on vitamin K, VKORC1 genotype and autism

Medical Hypotheses, 2016
Humans vary in the gene that encodes for Vitamin K epoxide reductase complex (VKORC1). Recent research has documented the protective effect of Vitamin K on neural cells and its role in maintaining normal neural development. Of interest, specific neural effects of Vitamin K overlap with key brain development aberrations, including those associated with ...
openaire   +2 more sources

Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes

Journal of Thrombosis and Thrombolysis, 2008
Polymorphisms in the vitamin K epoxide-reductase-complex-1 (VKORC1) and the cytochrome-P450-isozyme (CYP2C9) genes account for therapeutic responses to vitamin K antagonists (VKA). This study aimed to investigate the prevalence of VKORC1 and CYP2C9 polymorphisms among patients under phenprocoumon and its influence on the VKA dosage.Patients under ...
Berisha, Qazim, Claudia, Stöllberger, Walter, Krugluger, Astrid, Dossenbach-Glaninger, Josef, Finsterer   +4 more
openaire   +2 more sources

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 — Rationale and perspectives

Thrombosis Research, 2007
Warfarin is the most widely prescribed oral anticoagulant, but there is greater than 10-fold interindividual variability in the dose required to attain a therapeutic response. Information from pharmacogenomics, the study of the interaction of an individual's genotype and drug response, can help optimize drug efficacy while minimizing adverse drug ...
Tong, Yin, Toshiyuki, Miyata
openaire   +2 more sources

Influence of VKORC1 Haplotypes on Cardiovascular Disease

2008
Coronary heart disease is one of the leading causes of morbidity and mortality in Europe. Atherogenesis and vascular calcification have been linked to vitamin K and the downstream pathways of vitamin K dependant proteins acting in blood coagulation and calcium metabolism.
M. Watzka, A. Nebel, N. E. El Mokhtari, B. Ivandic, J. Müller, St. Schreiber, J. Oldenburg   +6 more
openaire   +1 more source

A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance

Blood, 2006
Abstract CYP2C9 and VKORC1 genetic variants are associated with low and intermediate warfarin dose requirements, but markers of high doses are less well characterized. We analyzed the VKORC1 coding sequence and known CYP2C9 and VKORC1 polymorphisms in 15 selected warfarin-resistant (dose, 80 to 185 mg/wk) and 8 warfarin-sensitive ...
Ronen, Loebstein, Ilana, Dvoskin, Hillel, Halkin, Manuela, Vecsler, Aharon, Lubetsky, Gideon, Rechavi, Ninette, Amariglio, Yoram, Cohen, Gie, Ken-Dror, Shlomo, Almog, Eva, Gak   +10 more
openaire   +2 more sources